“Abusive head trauma (AHT) is the leading cause of death from
traumatic brain injury in infants and the leading cause of death from
physical abuse in the United States,” said senior author Rachel Berger, M.D., M.P.H., chief of the Child Advocacy Center at Children’s Hospital and professor of pediatrics at the Pitt School of Medicine.
However, approximately 30 percent of AHT diagnoses are missed when
caretakers provide inaccurate histories or when infants have nonspecific
symptoms such as vomiting or fussiness. Missed diagnoses can be
catastrophic as AHT can lead to permanent brain damage and even death.
Berger and colleagues at Children’s Hospital and the Safar Center for Resuscitation Research at Pitt’s School of Medicine have long been researching approaches to detect acute intracranial hemorrhage in infants at risk.
In the current study, the researchers collaborated with Axela,
a Canadian molecular diagnostics company, to develop a sensitive test
that could reduce the chances of a missed diagnosis by using a
combination of three biomarkers along with a measure of the patient’s
level of hemoglobin, the protein that carries oxygen in blood. Axela’s
automated testing system allowed the researchers to measure multiple
biomarkers simultaneously using an extremely small amount of blood, an
important characteristic of a test designed to be used in infants.
To arrive at the formula, called the Biomarkers for Infant Brain Injury Score (BIBIS), for discriminating between infants with and without intracranial hemorrhage, the team used previously stored serum samples from a databank established at the Safar Center.
The team then evaluated the predictive capacity of the BIBIS value
in a second population of 599 infants who were prospectively enrolled at
three study sites in the United States. In addition to Children’s
Hospital, infants were enrolled at Ann and Robert H. Lurie Children’s Hospital in Chicago and Primary Children’s Hospital in
Salt Lake City. The test correctly detected acute intracranial
hemorrhage because of abusive head trauma approximately 90 percent of
the time, a much higher rate than the sensitivity of clinical judgement,
which is approximately 70 percent.
“The test is not intended to replace clinical judgement, which is
crucial,” said Dr. Berger. “Rather, we believe that it can supplement
clinical evaluation and in cases where symptoms may be unclear, help
physicians make a decision about whether an infant needs brain imaging.”
The specificity of the test—or the ability to correctly identify an
infant without bleeding of the brain who would not require further
evaluation—was 48 percent. The researchers aimed for the test to be
highly sensitive rather than maximizing accuracy, since missing a
diagnosis has more serious consequences than performing brain imaging in
babies without the condition.
“This study illustrates the benefits of being able to perform
highly sensitive tests at the point of care,” said Paul Smith, President
and CEO of Axela and a co-author of the study.
Pitt, Dr. Berger and Axela have filed a joint U.S. patent for the test.
Additional authors include Janet Fromkin, M.D., Richard Saladino,
M.D., and Patrick M. Kochanek, M.D., all from the University of
Pittsburgh; Brian J. Pak, Ph.D., Mariya D. Kolesnikova, Ph.D., David
Englert, Ph.D., and Paul T. Smith, from Axela Inc., Canada; Bruce E.
Herman, M.D., from the University of Utah; and Mary Clyde Pierce, M.D.,
from Ann and Robert H. Lurie Children’s Hospital.
The study was funded by National Institutes of Health grants R01HD055986 and NIHK23HD43843. The data in this publication is the basis for patent 62/334,345 filed on May 10, 2016.